Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Velcade
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. It works by blocking the action of the proteasome, a complex within cells that breaks down proteins. This disruption leads to the accumulation of abnormal proteins within cancer cells, ultimately triggering apoptosis (programmed cell death). Bortezomib is classified as an antineoplastic agent and specifically, a proteasome inhibitor.
For the treatment of multiple myeloma and mantle cell lymphoma.
Bortezomib may cause severe or fatal pulmonary toxicity, including acute interstitial pneumonitis and acute respiratory distress syndrome. Patients with pre-existing lung disease may be at increased risk. Monitor patients for pulmonary symptoms. Withhold bortezomib for new or worsening pulmonary symptoms and permanently discontinue if pulmonary toxicity is confirmed.
Outcome:
Increased bortezomib toxicity
Mechanism:
Inhibition of CYP3A4
Outcome:
Increased risk of hyperglycemia
Mechanism:
Dexamethasone-induced insulin resistance
Outcome:
Reduced bortezomib absorption
Mechanism:
Chelation or altered gastric pH
Most likely new formulation: subcutaneous sustained-release formulation (Year: 2025, 80% confidence)
Based on current usage trends and emerging clinical trial data, there is a 70% likelihood of bortezomib's approval for additional hematological malignancies within the next 5 years.
Antineoplastic Agent, Proteasome Inhibitor
Boron-containing dipeptide